Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - mycophenolate sodium, quantity: 384.8 mg (equivalent: mycophenolic acid, qty 360 mg) - tablet, enteric coated - excipient ingredients: magnesium stearate; crospovidone; triethyl citrate; maize starch; hypromellose; silicon dioxide; povidone; lactose; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - - indicated for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants. ,- indicated for induction and maintenance treatment of adult patients with who class iii, iv or v lupus nephritis.

Singapur - anglès - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - mycophenolate sodium 192.4mg eqv mycophenolic acid - enteric coated tablet - 192.4mg - mycophenolate sodium 192.4mg eqv mycophenolic acid 180mg

Singapur - anglès - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - mycophenolate sodium 384.8mg eqv mycophenolic acid - tablet, film coated - 384.8 mg - mycophenolate sodium 384.8mg eqv mycophenolic acid 360 mg

Singapur - anglès - HSA (Health Sciences Authority)

fisher scientific pte ltd - clinical chemistry - the cedia® mycophenolic acid (mpa) assay is an in vitro diagnostic medical device intended for the quantitative measurement of mycophenolic acid in human plasma using automated clinical chemistry analyzers as an aid in the management of mycophenolic acid therapy in renal and cardiac transplant patients.

Singapur - anglès - HSA (Health Sciences Authority)

siemens healthcare pte. ltd. - clinical toxicology - the emit® 2000 mycophenolic acid assay is for in vitro quantitative analysis of mycophenolic acid in human plasma as an aid in the management of mycophenolate mofetil therapy in transplant patients.

Singapur - anglès - HSA (Health Sciences Authority)

roche diagnostics asia pacific pte ltd - clinical chemistry - "in vitro test for the quantitative determination of total mycophenolic acid in serum or plasma as an aid in the management of mycophenolic acid therapy in renal and cardiac transplant patients on roche/hitachi cobas c systems."

Singapur - anglès - HSA (Health Sciences Authority)

roche diagnostics asia pacific pte ltd - immunology - it is an in vitro test for the quantitative determination of total mycophenolic acid in serum or plasma as an aid in the management of mycophenolic acid therapy in renal and cardiac transplant patients on cobas integra systems.

Malta - anglès - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - mycophenolic acid - gastro-resistant tablet - mycophenolic acid 360 mg - immunosuppressants

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 1005 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 149 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; silicon dioxide; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose; cetyl alcohol; sodium lauryl sulfate - short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to curam tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to curam tablets should not require the addition of another antibiotic due to the amoxycillin content of curam tablets.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate, quantity: 574 mg (equivalent: amoxicillin, qty 500 mg); potassium clavulanate, quantity: 149 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; purified talc; povidone; triethyl citrate; hypromellose; titanium dioxide; ethylcellulose; cetyl alcohol; sodium lauryl sulfate - short-term treatment of bacterial infection at the following sites when caused by amoxycillin/clavulanic acid sensitive, beta-lactamase producing organisms. skin and skin structure infections. urinary tract infections (uncomplicated and complicated). upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis. lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis. appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to curam tablets. however, when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the microbiological section, therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies. once these results are known, therapy should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to curam tablets should not require the addition of another antibiotic due to the amoxycillin content of curam tablets.